We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-12.68%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.45B
AUM Growth
-$497M
Cap. Flow
+$144M
Cap. Flow %
5.89%
Top 10 Hldgs %
73.47%
Holding
55
New
2
Increased
12
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$62.7M
2
KURA icon
Kura Oncology
KURA
+$40.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.4M
4
RVMD icon
Revolution Medicines
RVMD
+$32.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$28.3M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$35.3M
2
ETNB
89bio
ETNB
+$33.9M
3
GHRS icon
GH Research
GHRS
+$17.6M
4
XOMA
Xoma
XOMA
+$15.7M
5
ENGN icon
enGene Therapeutics
ENGN
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
26
Foghorn Therapeutics
FHTX
$262M
$19.4M 0.79%
5,302,000
– –
ITOS
27
DELISTED
iTeos Therapeutics
ITOS
$18.4M 0.75%
3,075,000
+750,000
+32% +$5.51M
FDMT icon
28
4D Molecular Therapeutics
FDMT
$526M
$14.7M 0.6%
4,561,289
+1,890,647
+71% +$8.91M
EPIX
29
DELISTED
ESSA Pharma
EPIX
$13.8M 0.56%
8,748,629
– –
ANNX icon
30
Annexon
ANNX
$832M
$13.5M 0.55%
7,000,000
– –
VSTM icon
31
Verastem
VSTM
$496M
$12.7M 0.52%
2,100,468
– –
RAPT
32
DELISTED
RAPT Therapeutics
RAPT
$11.3M 0.46%
1,154,695
– –
RPTX
33
DELISTED
Repare Therapeutics
RPTX
$10.2M 0.42%
10,333,600
– –
IMUX icon
34
Immunic
IMUX
$190M
$9.7M 0.4%
890,297
– –
AVTX icon
35
Avalo Therapeutics
AVTX
$993M
$8.3M 0.34%
1,036,679
– –
THRD
36
DELISTED
Third Harmonic Bio
THRD
$8.23M 0.34%
2,372,933
– –
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
$7.14M 0.29%
4,013,633
+2,200,000
+121% +$4.94M
TCRX icon
38
TScan Therapeutics
TCRX
$48.4M
$6.75M 0.28%
4,889,474
+1,900,000
+64% +$4.11M
MOLN
39
Molecular Partners
MOLN
$5.51M 0.22%
1,353,968
– –
IMA
40
ImageneBio Inc
IMA
$63.6M
$5.13M 0.21%
333,880
– –
FBRX icon
41
Forte Biosciences
FBRX
$1.57B
$4.61M 0.19%
594,282
– –
ALLK
42
DELISTED
Allakos
ALLK
$3.77M 0.15%
16,552,417
– –
CTMX icon
43
CytomX Therapeutics
CTMX
$686M
$3.32M 0.14%
5,228,461
– –
TENX icon
44
Tenax Therapeutics
TENX
$386M
$2.22M 0.09%
339,549
– –
IVA
45
Inventiva
IVA
$1.04B
$2.06M 0.08%
686,040
– –
CBIO
46
Crescent Biopharma
CBIO
$526M
$2M 0.08%
95,443
– –
SABS icon
47
SAB Biotherapeutics
SABS
$264M
$1.24M 0.05%
917,826
– –
NAMS icon
48
NewAmsterdam Pharma
NAMS
$3.24B
$1.21M 0.05%
+59,065
New +$1.31M
OVID icon
49
Ovid Therapeutics
OVID
$420M
$1.2M 0.05%
3,853,818
– –
ENGNW icon
50
enGene Therapeutics Warrants
ENGNW
$3.64M
$605K 0.02%
945,402
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2025 Portfolio in Review

As of Q1 2025, BVF Inc held 55 positions worth $2.45B, down 17% from $2.95B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BVF Inc deployed $144M of net new capital in Q1 2025, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was GH Research, an estimated $17.6M trimmed.

  • BVF Inc's largest Q1 2025 buy was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.
  • BVF Inc added most to Kura Oncology in Q1 2025, an estimated $40.4M increase.
  • BVF Inc's biggest Q1 2025 reduction was GH Research, cutting an estimated $17.6M.
  • BVF Inc fully exited Agios Pharmaceuticals in Q1 2025, selling an estimated $35.3M.
  • BVF Inc's ten largest holdings make up 73% of its $2.45B portfolio in Q1 2025.
  • BVF Inc opened 2 new positions and closed 4 in Q1 2025.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.45B.

Based on BVF Inc's 13F filing for Q1 2025, filed 15 May 2025.